Voting for Dynamic42 for the Thuringian Innovation Award

19. October 2018 In News

XXI Thuringian Innovation Award – Online Voting

Give us your vote! The online voting for the audience award at this year’s Thuringian Innovation Award is now open. Dynamic42 GmbH is taking part in the 21st edition of the traditional, state-wide competition with its liver sinusoid model in the category “Light and Life”. From 19 October to 2 November, all finalists can still vote for the public prize. This is sponsored by PricewaterhouseCoopers GmbH.

The jury assessments in the five categories “Tradition & Future”, “Industry & Material”, “Digital & Media”, “Light & Life” and “Special Award for Young Companies” have already been decided. The winners of all prizes will be announced at an evening event on 14. November in the Congress Hall Weimar. Interested parties can register here. The Thuringian Innovation Award is one of the most highly endowed state innovation awards in Germany. Prize money totalling € 100,000 will be awarded.

Until then, it’s all about collecting votes over the next two weeks. We call on all interested parties, partners, supporters and friends to participate in the online voting and to share their opinions.

Press Release | Dynamic42 launches Tumor Microenvironment Kit to advance complex in vitro cancer research

Dynamic42 GmbH announces the market launch of its Tumor Microenvironment (TME) Kit. The new product enables the creation of perfused 3D tumor models that reproduce the complexity of the human tumor microenvironment.

Press Release | Ohio Lumex Named Exclusive U.S. Distributor for Dynamic42’s Advanced Organ-on-Chip Technology

Ohio Lumex, a recognized leader in analytical solutions, is proud to announce a new partnership with German biotechnology company Dynamic42. Effective immediately, Ohio Lumex will serve as the exclusive distributor of Dynamic42’s innovative organ-on-chip technology in the United States.

Press Release | Tumour-on-chip model supports preclinical drug development on pancreatic cancer

Dynamic42 and Heinrich Heine University have developed a tumour-on-a-chip model that replicates the microenvironment of pancreatic ductal adenocarcinoma (PDAC). This 3D model allows for realistic drug testing and could accelerate the development of personalized therapies.

All News